Zentiva Enhances its Global Manufacturing Footprint by Signing an Agreement to Acquire Manufacturing Site in Ankleshwar, India

Prague, Mumbai and Ankleshwar, India (ots/PRNewswire) - Zentiva
Group, a.s. announces the signing of a Business Transfer Agreement
with Sanofi to acquire their manufacturing site in Ankleshwar, India.
This acquisition will help ensure the continued supply of
high-quality medicines to more patients by expanding the footprint
and agility of Zentiva's manufacturing network.

"Expanding our network of Zentiva's wholly-owned manufacturing
sites is a key factor in our future success, ensuring greater
security of supply for people living in Europe and beyond. It enables
us to innovate further to achieve operational excellence, enhance
productivity and accelerate growth," said Nick Haggar, Chief
Executive Officer of Zentiva. "We are strongly committed to the
growth and success of the Ankleshwar team and operations. The site
will be the largest in our network and the team in India will play a
central role in the operations of Zentiva."

With demand for high quality and affordable medicines increasing,
the acquisition reaffirms Zentiva's commitment to stand side-by-side
with pharmacists, healthcare professionals and decision makers in
improving access for patients.

Earlier in 2019, Zentiva enhanced its network with the acquisition
of Solacium in Romania and Creo in the United Kingdom, as well as
making multi-million Euro investments in Prague and Bucharest to
maximize manufacturing capabilities.

* This transaction is subject to receipt of regulatory approvals,
shareholders' approval and the completion of certain conditions as
defined under the Business Transfer Agreement.

About Ankleshwar Manufacturing Site

Established in 1987, the site has a chemistry & biotechnology
development centre, and manufactures both intermediates and
pharmaceutical formulations. A large producer of tablets, the
Ankleshwar site manufactures more than 6 billion tablets annually.

About Zentiva

Zentiva is a producer of high-quality affordable medicines serving
patients in Europe and beyond. With a dedicated team of more than
3,000 people and a network of production sites - including flagship
sites in Prague and Bucharest - Zentiva strives to be the champions
of branded and generic medicines in Europe to better support people's
daily healthcare needs.

At Zentiva it is our aspiration that healthcare should be a right
and not a privilege. More than ever, people need better access to
high quality affordable medicines and healthcare. We work in
partnership with physicians, pharmacists, wholesalers, regulators and
governments to provide the everyday solutions that we all depend on.

Media Contact:
Ines Windisch
Head of Corporate Affairs & Human Resources

ZENTIVA GROUP, a.s.
U Kabelovny 130 - 102 37 Prague 10 - Czech Republic
Cell: (+420) 601-341-444
E-mail: ines.windisch@zentiva.com
www.zentiva.com

Photo: https://mma.prnewswire.com/media/973827/Zentiva_Sanofi.jpg

Logo: https://mma.prnewswire.com/media/788903/Zentiva_Logo.jpg

ots Originaltext: Zentiva
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: Zentiva, übermittelt durch news aktuell